Ultragenyx Pharmaceutical Inc. Class Action Lawsuit Opportunity for Investors with Significant Losses

Investment Alert: Ultragenyx Pharmaceutical Inc. Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP has made an important announcement for those who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stock. Investors who bought shares between August 3, 2023, and December 26, 2025, have the chance to lead a class action lawsuit against the company for allegedly misleading information resulting in significant financial losses.

Rights of Investors during the Class Period

The class period references the timeline when purchases were made and highlights the potential legal ramifications for the pharmaceutical company and its executives. Ultragenyx focuses on developing treatments for rare and ultra-rare genetic diseases. The lawsuit, designated as Bailey v. Ultragenyx Pharmaceutical Inc., No. 26-cv-01097 (N.D. Cal.), accuses the company of violating the Securities Exchange Act of 1934 by providing inaccurate statements about its clinical studies.

Allegations Summary

The main allegations stated in the lawsuit include:
1. False Information on Drug Development: It is claimed that Ultragenyx and its top executives misrepresented the reliability of data regarding the drug setrusumab for Osteogenesis Imperfecta (OI), a genetic disorder characterized by fragile bones. The lawsuit alleges that the company's statements created a false perception of confidence concerning the drug's efficacy and the overall study results.
2. Misinterpreted Clinical Study Findings: The plaintiffs allege the company downplayed the risks of the Phase III Orbit study and the potential shortcomings of its initial Phase II studies.
3. Significant Stock Decline Post-Announcement: When Ultragenyx disclosed that the Phase III Orbit study did not meet its expected outcomes, it triggered a dramatic drop in stock value, which saw over a 25% decline following the announcement on July 9, 2025. By December 29, 2025, when further disappointing results were shared, Ultragenyx's stock plummeted by more than 42%. These events have raised serious concerns for shareholders who faced financial losses as a result.

Beat the Crowd: Become the Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, individuals who incurred substantial losses during the class period can apply to be the lead plaintiff. The lead plaintiff is identified as the person or party that has the largest financial stake in the outcome of the case, representing other investors in the class action lawsuit. It is noteworthy that participation as a lead plaintiff is not essential to any future recovery by other class members.

For investors looking to initiate or learn more about their participation in this legal action, information can be submitted through the official Robbins Geller website or by contacting attorney J.C. Sanchez directly at 800-449-4900.

About Robbins Geller Rudman & Dowd LLP

With a prominent standing in complex class action lawsuits, Robbins Geller is renowned for its efforts in securities fraud and shareholder rights litigation. The firm has ranked number one in securities class action recoveries, making substantial contributions totaling over $916 million in 2025 alone. Investors should stay updated on pertinent class action developments as more information becomes available.

Conclusion

The potential for a class action lawsuit brings both options and challenges for affected Ultragenyx shareholders. Those who believe they have been wronged should consider the implications of the news and assess the opportunity to seek redress through legal channels. As developments continue to unfold, the actions taken during this critical period may significantly impact the landscape for investors in Ultragenyx Pharmaceuticals.